Clinical Trials on Clear Cell Renal Cell Carcinoma Metastatic

Total 13316 results

Peking Union Medical College Hospital

Completed

68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients

Clear Cell Renal Cell Carcinoma

China
Hoosier Cancer Research Network
Bionomics Limited

Completed

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Australia, Singapore
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

United States, Canada, Italy, Finland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Kidney Cancer Research Bureau

Completed

Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors (FavorAx)

Carcinoma, Renal Cell | Clear Cell Renal Cell Carcinoma

Russian Federation
Instituto do Cancer do Estado de São Paulo
Pfizer

Unknown

Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib (SuAx)

Clear Cell Renal Cell Carcinoma

Brazil
GenSpera, Inc.

Completed

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

Clear Cell Renal Cell Carcinoma

United States
Peking University Third Hospital

Not yet recruiting

A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma

Ovarian Clear Cell Carcinoma
National Cancer Institute (NCI)

Terminated

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7

United States
Idera Pharmaceuticals, Inc.

Completed

Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

Renal Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen Research & Development, LLC

Active, not recruiting

Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Bladder Urothelial Carcinoma | Metastatic Kidney Carcinoma | Malignant Urinary System Neoplasm

United States
Sun Yat-sen University

Not yet recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma

China
National Cancer Institute (NCI)

Completed

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

Clear Cell Renal Cell Carcinoma | Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell Cancer

United States
MedImmune LLC

Completed

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Kidney Cancer | Clear Cell Renal Cell Carcinoma | Select Advanced Malignancies

United States, France, Canada, United Kingdom, Netherlands, Australia
GlaxoSmithKline

Completed

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Taiwan, Belgium, Israel, Australia, Hong Kong, China, Czech Republic
SCRI Development Innovations, LLC
Novartis; Genentech, Inc.

Completed

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
GSK Pharma; Lixte

Recruiting

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Ovarian Clear Cell Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type

United States
Duke University
Novartis; Pfizer

Completed

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)

Advanced Non-clear Cell Renal Cell Carcinoma

United States, Canada, United Kingdom
Roswell Park Cancer Institute
Novartis

Terminated

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Non Clear Cell Renal Cell Carcinoma (nccRCC)

United States
Heidelberg Pharma AG

Completed

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Kidney Cancer | Renal Cell Carcinoma

United States
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Phase 2 Study in Patients With MiT Tumors

Renal Cell Carcinoma (RCC) | Alveolar Soft Part Sarcoma (ASPS) | Clear Cell Sarcoma (CCS)

United States, Canada, United Kingdom
National Cancer Institute (NCI)

Completed

Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited

Not yet recruiting

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Stage II Renal Cell Cancer

United States
Region Skane
Lund University

Terminated

Diagnostic Imaging for Clear Cell Renal Cell Carcinoma (RCCSCAN)

Clear Cell Renal Cell Carcinoma

Sweden
Kura Oncology, Inc.
Mirati Therapeutics Inc.

Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001)

Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Carcinoma (ccRCC) | Solid Tumors With HRAS Alterations

United States
Centre hospitalier de l'Université de Montréal...
Bristol-Myers Squibb

Active, not recruiting

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

Melanoma | Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Brain Metastases, Adult | Clear-Cell Metastatic Renal Cell Carcinoma

Canada
Debiopharm International SA

Recruiting

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Cancer (ccRCC)

France, Australia
National Cancer Institute (NCI)

Recruiting

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Advanced Locoregional Melanoma | Clear Cell Histology

United States
Calithera Biosciences, Inc

Terminated

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Clear Cell Renal Cell Carcinoma (ccRCC)

United States
Elypta

Recruiting

AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC (AUR87A)

Clear Cell Renal Cell Carcinoma

United States, Sweden, United Kingdom, France, Denmark, Finland, Canada, Italy, Portugal, Spain
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma

United States
Tongji Hospital
Wuhan University; Henan Cancer Hospital; Qilu Hospital of Shandong University; Hubei... and other collaborators

Recruiting

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA)

Ovarian Clear Cell Carcinoma

China
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group...

Completed

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery (ASSURE)

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage II Renal Cell Cancer AJCC v7 | Stage I Renal Cell Cancer AJCC v6 and v7

United States, Canada, Puerto Rico
M.D. Anderson Cancer Center
Novartis

Completed

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Kidney Cancer

United States
Centre Hospitalier Universitaire de Saint Etienne

Terminated

Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer (CA9CRM)

Metastatic Renal Cell Carcinoma | Metastatic Kidney Cancer

France
Bradley A. McGregor, MD
Bristol-Myers Squibb; Exelixis

Recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell Carcinoma

United States
Rahul Aggarwal
AstraZeneca

Recruiting

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Endometrial Cancer | Stage III Renal Cell Cancer | Locally Advanced Malignant Solid Neoplasm | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Stage IV... and other conditions

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Exelixis

Active, not recruiting

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
Memorial Sloan Kettering Cancer Center

Recruiting

Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

Kidney Cancer | Clear Cell Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States
Radboud University Medical Center
ABX CRO; Telix International Pty Ltd

Completed

89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE

Clear Cell Renal Carcinoma

Netherlands
Duke University

Completed

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers

Metastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors

Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer | Clear Cell Renal Carcinoma

China
Scottish Clinical Trials Research Unit
Pfizer

Completed

Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion (NAXIVA)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Non-metastatic Renal Cell Carcinoma

United Kingdom
Calithera Biosciences, Inc

Completed

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (CANTATA)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States, United Kingdom, Australia, France, Italy, Germany, Spain, New Zealand
Active Biotech AB

Completed

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Renal Cell Carcinoma | Pancreatic Cancer | Non-Small-Cell Lung Carcinoma

United States, Norway, United Kingdom
Qianfoshan Hospital

Recruiting

Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

China
Brown University
Bristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...

Active, not recruiting

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Extra Renal Origin | Clear Cell Adenocarcinoma

United States

Clinical Trials on Clear Cell Renal Cell Carcinoma Metastatic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations